Physician profile
Charles T Dickson
NPI 1043250533
$1,147.56
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $399 · 2021: $19.11 · 2022: $51.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $379.21 | 2019-2020 | |
| Abbvie INC. | $240.88 | 2019-2022 | |
| Janssen Biotech, INC. | $207.72 | 2019-2022 | |
| Astellas Pharma US INC | $133.94 | 2019 | |
| Allergan, INC. | $38.82 | 2019-2020 | |
| Healthtronics Stone Solutions, LLC | $37.28 | 2019 | |
| Blue Earth Diagnostics | $35.19 | 2019 | |
| Ethicon US, LLC | $27.94 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $25.45 | 2019 | |
| Coloplast Corp | $21.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.